World Mental Health Day 2025

World Mental Health Day 2025

Oct 10, 2025

Copenhagen, Denmark 

Each year on World Mental Health Day, we are reminded that mental health is a universal human right, one that deserves the same attention, care, and access as physical health.

Across the world, millions of people continue to face mental health challenges, yet access to quality care remains limited, and stigma persists. At Monsenso, we believe that digital innovation can help close this gap by making prevention, treatment, and self-management more accessible, personalised, and data-driven.

Empowering people through digital health

Through our innovation projects — including MentBest, PERSONAE, DECODE, and Smart-Bipolar — as well as our clinical implementations, we collaborate with partners across Europe to:

  • Improve access to mental health support through digital platforms
  • Empower individuals and families with real-time insights and self-management tools
  • Support clinicians with data-driven decision-making for timely and effective interventions

By combining technology, research, and collaboration, Monsenso aims to enable a more proactive and inclusive approach to mental health care. Digital tools can bridge the gap between individuals and professionals, promote early intervention, and ultimately improve outcomes for those affected by mental health conditions.

Our mission at Monsenso

At Monsenso, our mission is to improve mental health and wellbeing through digital innovation. We work to empower individuals, carers, and healthcare professionals by providing tools that support self-management, enhance communication, and enable data-driven care. By doing so, we strive to make mental health services more efficient, scalable, and person-centred — helping ensure that no one is left behind in accessing the support they need.

A shared mission for change

On this World Mental Health Day, we stand together with our partners and the global community in the mission to ensure that everyone, everywhere, has access to quality mental health care. Together, we can build a future where mental health is valued, supported, and protected for all.

To learn more or explore a pilot or integration, book a demo or get in touch via our website.

 

Solution
First Participant Recruited in PhaseV Study on Chronic Spontaneous Urticaria

First Participant Recruited in PhaseV Study on Chronic Spontaneous Urticaria

Aug 20, 2025

Copenhagen, Denmark 

We are pleased to share a new milestone from the national cross-sector innovation programme, PhaseV, supported by Innovation Fund Denmark. The project is pioneering a digital-first approach to decentralised, real-world clinical studies across several disease areas.

The Work Package 6 (WP6) study, focusing on chronic spontaneous urticaria (CSU), has successfully recruited its first participant. This marks the beginning of an important research effort that will explore how digital tools can support patients and clinicians in monitoring symptoms and treatment over time.

ABOUT THE PROJECT

The CSU study aims to develop and validate novel digital assessment tools that use patient-submitted photographs and questionnaires to remotely track urticaria severity in daily life. In addition, the study will explore how lifestyle and environmental factors (such as activity and sleep) influence CSU symptom flares, and will test new methods for conducting decentralised clinical research, including remote informed consent.

In PhaseV, participants use connected devices and a study app developed by Monsenso to report patient-generated health data from home. Clinicians can access these data through a dedicated web portal, helping to bridge the gap between daily life and the clinic.

The Urticaria study is one of three studies within PhaseV, alongside studies in obesity and diabetic foot ulcers, all aiming to demonstrate how decentralised designs can make clinical research more efficient, patient-friendly, and closer to real-world practice.

We look forward to following the progress of the CSU study and the insights it will generate for the future of clinical research and patient care.

 

Private-PUBLIC partnership

The consortium is led by Monsenso and includes partners across academia, healthcare, industry, and innovation: Aarhus University, Research Unit for General Practice (FEAP), Bispebjerg Hospital, Steno Diabetes Center Aarhus, Aarhus Municipality, the Danish Technological Institute, the Alexandra Institute, the Copenhagen Institute for Futures Studies, Danish Life Science Cluster, Novo Nordisk, and Novartis.

PhaseV aims to deliver a scalable digital platform for effective decentralised recruitment, continuous data capture, and phase-V style real-world studies that can strengthen patient care and decision-making.

For more information about the project and its progress, visit the PhaseV website or the Danish Life Science Cluster project page, or follow Monsenso on LinkedIn.

 To learn more or explore a pilot or integration, book a demo or get in touch via our website.

Solution
Missed Our Webinar on Digital Markers and Health Technology? Here Are the Key Takeaways

Missed Our Webinar on Digital Markers and Health Technology? Here Are the Key Takeaways

Aug 12, 2025

Copenhagen, Denmark 

On the 11th of June, we hosted our webinar Unlocking the Future of Mental and Behavioural Health with Digital Biomarkers and Health Technology. Our speakers, Maria Faurholt-Jepsen, Associate Professor and psychiatrist at the University of Copenhagen, and Emil Kortsen, Product Manager at Monsenso, explored how digital tools are transforming health research, monitoring, and treatment.

You can watch the full session on-demand here: view the recording.

From smartphone-based symptom tracking to AI-powered personalised care, here are the main takeaways:

1. Digital phenotyping is transforming mental health care

Smartphone-based solutions can collect both active (self-reported) and passive (sensor-derived) data. This fine-grained, real-time information provides clinicians with a more accurate picture of patient wellbeing, reducing reliance on memory and subjective observation.

2. Mood instability matters – and we can measure it

Longitudinal studies reveal that mood instability, especially in bipolar type II disorder, is more common and impactful than previously thought. Even between episodes, these fluctuations can significantly reduce quality of life, functioning, and resilience.

3. Passive data can detect symptom changes

Patterns in phone usage, mobility, and even voice features correlate strongly with depressive and manic states. For example, decreased movement and increased behavioural irregularity can distinguish bipolar from unipolar depression.

4. Clinical trials are integrating digital biomarkers

Ongoing trials are using daily monitoring to measure treatment response, ranging from medication effects to psychoeducation programmes. While some studies have not shown primary outcome changes, they have demonstrated benefits such as reduced stress, less rumination, and improved quality of life.

5. Personalised, stepped care is already here

The Personae Project uses digital tools to deliver customised treatment for depression. Based on validated questionnaires, it creates tailored therapy content and adjusts care intensity in real time depending on each patient’s progress.

6. Digital tools bridge psychiatric and physical healthcare

In the Phase V Project, digital monitoring is helping manage diabetic foot ulcers. Patients and home-care staff can submit wound assessments and photos to hospital specialists, enabling timely interventions and reducing unnecessary visits. Phase V also includes studies in obesity and urticaria.

7. Engagement thrives on relevance

Projects have achieved high compliance (often 75%+) when patients see real value in the system. Personalised recommendations, timely feedback, and flexibility to “hop on and off” monitoring are key to sustained use.

8. AI will power the next generation of digital care

From detecting symptom shifts to personalising interventions, AI is already being trialled in projects like MENTBEST and Personae. These tools aim to provide predictive insights while meeting strict ethical and data protection standards.

Join us next time

Don’t miss our next webinar: 2 September 2025 at 15:30 CEST – Personalised, Data-Driven Blended Care: Insights from the Personae Project.
Discover how personalised, data-driven care can transform outcomes across mental health services.

Register here

To learn more or explore a pilot or integration, book a demo or get in touch via our website.

 

Solution
The Power of Citizen-Generated Health Data – a Business Review Life Science Podcast

The Power of Citizen-Generated Health Data – a Business Review Life Science Podcast

Aug 4, 2025

Copenhagen, Denmark 

Monsenso is happy to announce that our CEO, Thomas Lethenborg, recently participated in the Business Review Life Science podcast, joining a compelling panel discussion on the transformative potential of real-world patient-reported data.

The episode, titled “Borgernes egne sundhedsdata” (“Citizen-Generated Health Data”), will be aired on August 11th and features key voices from the ongoing Phase V innovation project.

Hosted by Heidi Bendtsen Nielsen, the podcast explores how personal health data – such as information collected via smartphones, blood pressure monitors, or smartwatches – can be used to enhance treatment outcomes, support prevention, and relieve pressure on healthcare systems.

Thomas Lethenborg was joined by:

  • Frederik Knud Nielsen, Healthcare Partnership Director at Novartis
  • Frederik Mølgaard Thayssen, Principal Project Manager at the Alexandra Institute

Together, the panel addressed several timely and critical questions:

  • What opportunities do Danes have today to collect and contribute their own health data?
  • How can these data be validated and effectively integrated into healthcare practices?
  • What barriers – regulatory, ethical, or technical – still need to be overcome?
  • How can public-private collaborations, like Phase V, unlock the full potential of data-driven healthcare?

“At Monsenso, we see real-world data as a key enabler of more personalised, preventive, and efficient healthcare”, said Thomas Lethenborg. “This podcast gave us a great platform to highlight not only the technological possibilities but also the importance of patient involvement and responsible data use.”

The discussion also emphasised the need for stronger political commitment to support personalised, data-driven innovation in healthcare and showcased examples of successful collaborations between industry and the public sector – including the Phase V initiative.

Listeners can access the full episode (in Danish) on the Business Review Life Science platform.

To learn more or explore a pilot or integration, book a demo or get in touch via our website.

 

Solution
Monsenso supports UK research on treatment-resistant depression

Monsenso supports UK research on treatment-resistant depression

Jul 24, 2025

Copenhagen, Denmark

Monsenso delivers digital research platform for groundbreaking UK project on treatment-resistant depression.

Monsenso A/S is proud to announce its strategic role as the digital technology partner for the DECODE project in the United Kingdom. The initiative, led by the University of Birmingham, in collaboration with the Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust, and Nottinghamshire Healthcare NHS Foundation Trust, is focused on transforming clinical research and care for patients with treatment-resistant depression (TRD).

As part of the project, Monsenso’s digital platform will enable stratified recruitment, remote data collection, and standardised clinical endpoint measurement across multiple NHS sites — laying the groundwork for improved precision in depression research and future interventions.

Addressing a Critical Public Health Challenge

Treatment-resistant depression (TRD) affects almost half of patients diagnosed with major depressive disorder meaning they do not respond to two or more oral antidepressants, and TRD is associated with poorer outcomes, including high comorbidity, suicidality, and economic burden. 

The DECODE project aims to build a digitally enabled recruitment and monitoring infrastructure to better identify, understand, and ultimately treat this complex condition.

Recruitment is expected to begin in Q3 2025, with Monsenso’s platform playing a pivotal role in data collection and patient stratification.

Quote from Monsenso CEO

“We are honoured to support such an important national initiative addressing one of the most challenging areas in mental health. Monsenso’s platform is designed to help healthcare providers and researchers make better, data-driven decisions through real-time digital monitoring and standardised assessments,” said Thomas Lethenborg, CEO of Monsenso.

“This project reaffirms our strategic positioning as a trusted partner in supporting decentralised, real-world data studies across Europe with healthcare, academic institutions and pharmaceuticals.”

Strategic Importance for Monsenso

  • Expansion into the UK: Strengthens Monsenso’s footprint within the UK healthcare ecosystem, particularly within the NHS and leading academic partners.
  • Scalable digital, decentralised research model: Demonstrates the scalability and flexibility of Monsenso’s platform for decentralised multi-site health research.
  • Expansion possibilities: If successful, the DECODE project has potential to pave the way for geographic expansion and follow-on precision-medicine studies.
  • Validation of product-market fit: Reinforces Monsenso’s role in delivering regulated, patient-centric digital tools that meet the complex needs of decentralised, real-world studies in psychiatric conditions and beyond.

Academic and Clinical Endorsement

Professor Steven Marwaha, Co-director of the Midlands Mental Health Mission and Professor at the University of Birmingham, stated:

“This partnership with Monsenso enables us to streamline and enhance the way we recruit patients and assess outcomes. By integrating continuous data collection, digital phenotyping tools and standardising clinical endpoints, we can accelerate our understanding of treatment-resistant depression and drive more precise and personalised future interventions.

Click the button below for more information about the Monsenso solution.

Solution